Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Philippe Arnault

Showing results (51-60 of 67) with videos related to

Pageof 7
Sort By:
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 12, 2024
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM networkRobin Zagala, Stephane Dalle, Marie Beylot-Barry, et al.
Eclinicalmedicine|December 24, 2024
When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Laurent Mortier, Stéphane Dalle, et al.
JAMA Dermatology|May 2, 2019
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalAnaïs Vallet, Bastien Oriano, Laurent Mortier, et al.
The British Journal of Dermatology|November 28, 2024
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world settingKarine Billard, Laurent Mortier, Olivier Dereure, et al.
International Journal of Cancer|January 11, 2021
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational studySandrine Monestier, Stéphane Dalle, Laurent Mortier, et al.
The Journal of Investigative Dermatology|August 28, 2017
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer NetworkJulie Delyon, Sylvie Chevret, Thomas Jouary, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2026
Prognostic classification of skin adnexal carcinomas: Results from a prospective study of 980 patients in the French CARADERM networkRobin Zagala, Stephane Dalle, Brigitte Balme, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in FranceMarguerite Kandel, Aurélie Bardet, Stéphane Dalle, et al.
Pageof 7

Showing results (51-60 of 67) with videos related to

Sort By:
Pageof 7
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 19, 2011
Skin tumors induced by sorafenib; paradoxic RAS-RAF pathway activation and oncogenic mutations of HRAS, TP53, and TGFBR1Jean Philippe Arnault, Christine Mateus, Bernard Escudier, et al.
Annals of the Rheumatic Diseases|July 5, 2022
Risk of irAEs in patients with autoimmune diseases treated by immune checkpoint inhibitors for stage III or IV melanoma: results from a matched case-control studyLéo Plaçais, Stéphane Dalle, Olivier Dereure, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|June 12, 2024
Radiotherapy and prognostic factors in adnexal carcinomas: A retrospective study of 657 patients from the French CARADERM networkRobin Zagala, Stephane Dalle, Marie Beylot-Barry, et al.
Eclinicalmedicine|December 24, 2024
When to stop immunotherapy for advanced melanoma: the emulated target trialsMathilde Amiot, Laurent Mortier, Stéphane Dalle, et al.
JAMA Dermatology|May 2, 2019
Association of Time From Primary Diagnosis to First Distant Relapse of Metastatic Melanoma With Progression of Disease and SurvivalAnaïs Vallet, Bastien Oriano, Laurent Mortier, et al.
The British Journal of Dermatology|November 28, 2024
The efficacy and safety of first-line metastatic melanoma treatment with ipilimumab + nivolumab vs. nivolumab in a real-world settingKarine Billard, Laurent Mortier, Olivier Dereure, et al.
International Journal of Cancer|January 11, 2021
Effectiveness and safety of nivolumab in patients with advanced melanoma: A multicenter, observational studySandrine Monestier, Stéphane Dalle, Laurent Mortier, et al.
The Journal of Investigative Dermatology|August 28, 2017
STAT3 Mediates Nilotinib Response in KIT-Altered Melanoma: A Phase II Multicenter Trial of the French Skin Cancer NetworkJulie Delyon, Sylvie Chevret, Thomas Jouary, et al.
European Journal of Cancer (Oxford, England : 1990)|April 5, 2026
Prognostic classification of skin adnexal carcinomas: Results from a prospective study of 980 patients in the French CARADERM networkRobin Zagala, Stephane Dalle, Brigitte Balme, et al.
Current Oncology (Toronto, Ont.)|December 22, 2022
Cost-Effectiveness Analysis of Sequential Treatment Strategies for Advanced Melanoma in Real Life in FranceMarguerite Kandel, Aurélie Bardet, Stéphane Dalle, et al.
Pageof 7